因美国食品药品监督管理局（FDA）指出其针对过敏反应的实验性药物上市申请材料存在不足，Aquestive Therapeutics Inc. 股价遭遇重挫，单日跌幅高达37.2%。这一监管层面的负面消息引发了市场对该公司新药获批前景的严重担忧，导致投资者信心受挫，大规模抛售股票。
因美国食品药品监督管理局（FDA）指出其针对过敏反应的实验性药物上市申请材料存在不足，Aquestive Therapeutics Inc. 股价遭遇重挫，单日跌幅高达37.2%。这一监管层面的负面消息引发了市场对该公司新药获批前景的严重担忧，导致投资者信心受挫，大规模抛售股票。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.